Previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (IHC 1+ and greater) research hub

Disitamab vedotin with pembrolizumab vs chemotherapy in previously untreated urothelial cancer expressing HER2

This study tests a new medicine combination for people with advanced bladder cancer that carries a protein called HER2. Researchers want to see if combining two drugs, disitamab vedotin and pembrolizumab, works better and helps people live longer than standard chemotherapy.